Table 3.

Attenuation of the association between method of detection and disease-free survival after adjusting for clinical variables and CNIs for study population (n = 850)

Factors adjusted forHER (95% CI) for screen vs. symptom detectedFreedman statistic, %Freedman statistic, P
None0.66 (0.50–0.88)
Race0.66 (0.49–0.88)0.130.97
Histology0.66 (0.5–0.89)1.80.53
Tumor subtype0.68 (0.50–0.93)7.00.38
Ki670.70 (0.50–0.98)150.21
Hormonal therapy0.70 (0.53–0.94)15.10.06
Nodal status0.71 (0.53–0.95)17.90.04
Chemotherapy0.71 (0.53-0.96)17.40.14
5 CNIs0.72 (0.53–0.96)20.30.06
Nuclear grade0.73 (0.55–0.99)25.80.08
Age at diagnosis0.74 (0.54–1.003)270.12
Tumor size0.75 (0.55–1.01)29.50.04
Tumor size + nodal status + age + grade + Ki670.86 (0.59–1.24)63.50.04
Tumor size + nodal status + age + grade + Ki67 + 5 CNIs0.93 (0.64–1.36)82.40.02